Browse the evidence

Visceral and ectopic fat accumulation strongly predicts adverse lipid patterns, insulin resistance, and cardiovascular events.

Focus on reducing visceral and ectopic fat to improve lipid profiles and reduce cardiovascular risk.

Lifestyle interventions demonstrate favorable effects on lipid metabolism independent of weight loss.

Encourage patients to adopt lifestyle changes for lipid management, even if weight loss is not achieved.

Roux-en-Y gastric bypass was associated with less gastroesophageal reflux disease (GERD)-related symptoms compared to sleeve gastrectomy.

Surgeons may prefer Roux-en-Y gastric bypass for patients concerned about GERD symptoms.

GLP-1 receptor agonists (GLP-1 RAs) have been presumed to positively influence erectile function.

GLP-1 RAs may be considered in the management of erectile function in diabetic patients.

Obesity significantly influences the incidence and progression of various cancers.

Practitioners should consider obesity as a critical factor in cancer risk assessment.

Obesity is linked to increased cancer susceptibility and adverse prognostic outcomes.

Awareness of obesity's impact on cancer outcomes is essential for patient management.

Surgical therapies including laparoscopic bariatric surgery represent an important treatment strategy in obese patients.

Practitioners should consider bariatric surgery for eligible obese patients.

Combining medications with bariatric surgery may improve long-term outcomes for T2DM management.

Clinicians should consider integrating pharmacotherapy with surgical interventions for better management of T2DM.

Expert consensus has defined a state of diabetes remission where treatment can induce sustained normalization of glucose levels.

Understanding this definition can help practitioners set realistic treatment goals.

Tirzepatide was recently approved for the management of obesity.

Tirzepatide can be considered as a treatment option for obesity management.

Tirzepatide manages blood sugar levels and enhances weight loss more than GLP-1 receptor agonists.

Tirzepatide may be more effective than GLP-1 receptor agonists for patients needing blood sugar and weight management.

Continuing GLP-1 or GIP agonists before upper endoscopy increases the risk of clinically significant residual gastric volume (RGV).

Practitioners should consider holding GLP-1 or GIP agonists prior to upper endoscopy to reduce the risk of RGV.

Holding one dose of GLP-1 or GIP agonists significantly reduces the risk of clinically significant RGV.

Holding the medication prior to the procedure is advisable to minimize RGV risk.

Clear liquids the day prior to the procedure may mitigate the risk of clinically significant RGV regardless of GLP-1/GIP use.

Encouraging clear liquids before procedures may help reduce RGV risk.

MNs hold promise in improving the quality of life for individuals struggling with obesity and its associated comorbidities.

MNs may enhance treatment efficacy and patient outcomes in obesity management.

Tirzepatide is available for the treatment of hyperglycemia in patients with type 2 diabetes.

Practitioners can consider tirzepatide as a treatment option for managing hyperglycemia in type 2 diabetes patients.

Traditional resistance training and blood flow restriction training showed conflicting results for improving quadriceps size.

Practitioners should be cautious when applying traditional resistance and blood flow restriction training due to inconsistent outcomes.

Powerlifters had significantly greater training duration and absolute squat and bench press 1RM compared to recreationally strength-trained subjects.

Powerlifting training may lead to greater strength gains compared to recreational strength training.

Significant negative relationships were found between 2-lift Wilks score and shoulder extension and horizontal abduction, as well as hip flexion and extension.

Improving shoulder and hip ROM may enhance strength performance in powerlifters.

Sarcopenia is characterized by the progressive and generalized loss of muscle mass and strength, negatively impacting health and quality of life.

Understanding sarcopenia is crucial for developing interventions to improve health in aging populations.

Tirzepatide is a novel treatment option for Type 2 diabetes mellitus (T2DM) that may benefit individuals with cardiovascular disease or heart failure.

Tirzepatide may be considered for T2DM patients with cardiovascular concerns.

Key gut hormones such as GLP-1, OXM, and PYY play a role in ameliorating Type 2 diabetes mellitus.

Therapies targeting GLP-1, OXM, and PYY may be beneficial for managing DM2.

Seventy adults with a BMI between 25 and 40 were randomly assigned to either a standard-of-care treatment group or a mobile technology group.

This indicates the study's focus on overweight and obese adults for weight loss interventions.

Participants in the mobile group received personal digital assistants for self-monitoring diet and physical activity.

This suggests that technology can aid in self-monitoring for weight loss.